Zheng Wang1, Xiaonan Wu2, Xiaohong Han3, Gang Cheng2, Xinlin Mu4, Yuhui Zhang5, Di Cui1, Chang Liu6, Dongge Liu1, Yuankai Shi3. 1. Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China. 2. Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China. 3. Department of Medical Oncology, National Cancer Center/Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China. 4. Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China. 5. Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 6. Department of Medical Oncology, PLA Army General Hospital, Beijing 100700, China.
Abstract
OBJECTIVE: The relationship between anaplastic lymphoma kinase (ALK) expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy of ALK-tyrosine kinase inhibitor therapy is uncertain. METHODS: Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence in situ hybridization (FISH) was used to verify the ALK gene status in Ventana IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded. RESULTS: Of the 313 MPE samples, 27 (8.6%) were confirmed as ALK expression-positive, and the Ventana IHC ALK (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor receptor (EGFR) MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response (CR), 5 had partial response (PR) and 3 had stable disease (SD). CONCLUSIONS: The ALK gene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma.
OBJECTIVE: The relationship between anaplastic lymphoma kinase (ALK) expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy of ALK-tyrosine kinase inhibitor therapy is uncertain. METHODS: Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence in situ hybridization (FISH) was used to verify the ALK gene status in Ventana IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded. RESULTS: Of the 313 MPE samples, 27 (8.6%) were confirmed as ALK expression-positive, and the Ventana IHC ALK (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor receptor (EGFR) MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response (CR), 5 had partial response (PR) and 3 had stable disease (SD). CONCLUSIONS: The ALK gene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma.
Authors: Hye-Suk Han; Dae-Woon Eom; Joo Heon Kim; Kyung-Hee Kim; Hyang-Mi Shin; Jin Young An; Ki Man Lee; Kang Hyeon Choe; Ki Hyeong Lee; Seung Taik Kim; Ji Hae Koo; Ho-chang Lee; Ok-Jun Lee Journal: Clin Lung Cancer Date: 2011-05-20 Impact factor: 4.785
Authors: Maria D Lozano; Javier J Zulueta; Jose I Echeveste; Alfonso Gúrpide; Luis M Seijo; Salvador Martín-Algarra; Anabel Del Barrio; Ruben Pio; Miguel Angel Idoate; Tania Labiano; Jose Luis Perez-Gracia Journal: Oncologist Date: 2011-05-14
Authors: Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi Journal: J Thorac Oncol Date: 2013-07 Impact factor: 15.609
Authors: Umberto Malapelle; Claudio Bellevicine; Caterina De Luca; Maria Salatiello; Alfonso De Stefano; Danilo Rocco; Nicla de Rosa; Fabiana Vitiello; Stefania Russo; Francesco Pepe; Antonino Iaccarino; Pietro Micheli; Alfonso Illiano; Chiara Carlomagno; Franco Vito Piantedosi; Giancarlo Troncone Journal: Cancer Cytopathol Date: 2013-06-18 Impact factor: 5.284
Authors: Katja Tuononen; Virinder Kaur Sarhadi; Aino Wirtanen; Mikko Rönty; Kaisa Salmenkivi; Aija Knuuttila; Satu Remes; Aino I Telaranta-Keerie; Stuart Bloor; Pekka Ellonen; Sakari Knuutila Journal: Biomed Res Int Date: 2013-01-20 Impact factor: 3.411